Olema Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Directors make major company decisions, so their election shows who will lead the company going forward.
A partnership with a major company like Bayer validates the drug candidate and could lead to future sales.
Good safety data means the experimental drug can keep advancing toward helping patients and generating revenue.
Quarterly results show if the company is spending money wisely and how long cash will last.
Quarterly results show if the company is spending money wisely and how long cash will last.
A bigger office shows the company is growing, though it also means higher costs to pay each month.
New independent directors bring fresh expertise and help protect shareholder interests through oversight.
Stocky reads Olema Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Olema Pharmaceuticals, Inc.'s most recent tracked filing was a 8-K on 23 Jun 2026: Stockholders elect four directors through 2029.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.